络病研究的传承与创新

李红蓉; 吴以岭

doi:10.14148/j.issn.1672-0482.2022.1075

络病研究的传承与创新

doi: 10.14148/j.issn.1672-0482.2022.1075

李红蓉^{1, 2,},
吴以岭^{3, 4, ,}

1.
河北以岭医院国家中医药管理局中医络病学重点学科，河北石家庄 050091
2.
河北以岭医药研究院国家中医药管理局重点研究室(心脑血管络病)，河北石家庄 050035
3.
河北以岭医药研究院络病重点实验室，河北石家庄 050035
4.
络病研究与创新中药国家重点实验室，河北石家庄 050035

基金项目:

国家重点研发计划 2017YFC1700500

国家中医药管理局中医药多学科交叉创新团队 ZYYCXTD-D-202206

中国工程院咨询项目 2022-XY-45

河北省中医药管理局研计划项目 2022216

河北省中医药管理局重点项目 Z2022020

河北省中医药管理局科研计划项目 2023172

河北省自然科学基金项目 H2022106065

详细信息

作者简介:
李红蓉，女，主治医师，E-mail：lihongrong@yiling.cn

吴以岭, 主任中医师，教授，博士生导师，中国工程院院士，中医络病学科创立者和学科带头人，络病研究与创新中药国家重点实验室主任，国家中医药管理局络病重点研究室主任，国家心血管病中心专家委员会副主任委员，中国医学科学院学部委员，中国中医科学院学部委员，中国中西医结合学会名誉会长，中华中医药学会名誉副会长，世界中医药学会联合会副主席，中国老年医学学会副会长，中华中医药学会络病分会名誉主任委员，世界中医药学会联合会抗衰老专业委员会会长

通讯作者:
吴以岭，男，教授，博士生导师，中国工程院院士，主要从事中医络病理论研究，E-mail：yiling@yiling.cn

中图分类号: R228
计量
- 文章访问数: 378
- HTML全文浏览量: 51
- PDF下载量: 46
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-03
- 网络出版日期: 2022-12-15
- 发布日期: 2022-12-10

Inheritance and Innovation of Luobing Research

LI Hong-rong^{1, 2
,},
WU Yi-ling^{3, 4
, ,}

1.
Key Discipline of TCM Luobing of State Administration of Traditional Chinese Medicine, Hebei Yiling Hospital, Shijiazhuang 050091, China
2.
Key Research Room of State Administration of Traditional Chinese Medicine, Institute of Hebei Yiling Medicine, Shijiazhuang 050035, China
3.
Key Research Room of Luobing, Institute of Hebei Yiling Medicine, Shijiazhuang 050035, China
4.
Study and Innovation of Luobing of State Key Research Room of Traditional Chinese Medicine, Shijiazhuang 050035, China

摘要

摘要: 传承精华，守正创新是新时代中医药事业和产业高质量发展的根本遵循。以“络病证治”为总纲，以“脉络学说”“气络学说”为两翼的中医络病理论体系就是传承了历代医家关于络病的学术思想、理论观点、临证经验并结合现代科学技术系统构建的创新理论，开辟了临床重大疾病防治的新途径。以络病理论为指导，以现代基础研究和临床研究为基石，将临床有效组方转化为系列中药创新药物，在病毒类呼吸系统传染病、微血管病变、神经-内分泌-免疫系统疾病防治及抗衰老方面取得了重大突破。
- 络病理论 /
- 络病证治 /
- 脉络学说 /
- 气络学说 /
- 传承精华 /
- 守正创新
Abstract: Inheriting essence and keeping integrity and innovation are the fundamental principles for the high-quality development of TCM and its industry in the new era. The theoretical system of Luobing of TCM, with the general outline of " diagnosis and treatment principle of Luobing " and the two wings of "Mailuo theory" and "Qiluo theory", inherits the academic thoughts, theoretical views and clinical experience of successive doctors on Luobing and combines with modern science and technology to construct an innovative theory systematically, which has opened up a new way for the prevention and treatment of major clinical diseases. Guided by the Luobing theory and based on modern basic and clinical research, the clinical effective prescriptions have been transformed into a series of innovative traditional Chinese medicine drugs, and major breakthroughs have been made in the prevention and treatment of viral respiratory infectious diseases, microangiopathy and neuro-endocrine-immune system diseases and anti-aging.
- Luobing theory /
- diagnosis and treatment principle of Luobing /
- Mailuo theory /
- Qiluo theory /
- inheriting essence /
- keeping integrity and innovation

HTML全文

参考文献(79)

[1]	吴以岭. 中医理论创新提高中药原创水平[C]. 南京: 中国药学大会暨第十二届中国药师周, 2012: 3185-3186. WU YL. Innovation in TCM theory to improve the originality of Chinese medicine[C]. Nanjing: Proceedings of the 2012 Chinese Pharmacy Congress and the 12th Chinese Pharmacists Week, 2012: 3185-3186.
[2]	吴以岭. 络病理论体系构建及其学科价值[J]. 前沿科学, 2007, 1(2): 40-46. doi: 10.3969/j.issn.1673-8128.2007.02.006 WU YL. Systemic construction and subject value of luobing theory[J]. Front Sci, 2007, 1(2): 40-46. doi: 10.3969/j.issn.1673-8128.2007.02.006
[3]	吴以岭. 络病学说形成与发展的三个里程碑(一)[J]. 疑难病杂志, 2004, 3(2): 89-91. doi: 10.3969/j.issn.1671-6450.2004.02.008 WU YL. Three milestones in the formation and development of the theory of collateral diseases (Ⅰ)[J]. J Diffcult Complicat Cases, 2004, 3(2): 89-91. doi: 10.3969/j.issn.1671-6450.2004.02.008
[4]	吴以岭. 络病学说形成与发展的三个里程碑(二)[J]. 疑难病杂志, 2004, 3(3): 149-151. doi: 10.3969/j.issn.1671-6450.2004.03.009 WU YL. Three milestones in the formation and development of the theory of collateral diseases (Ⅱ)[J]. J Diffcult Complicat Cases, 2004, 3(3): 149-151. doi: 10.3969/j.issn.1671-6450.2004.03.009
[5]	魏聪, 贾振华, 常丽萍. 中医络病学科研究回顾与展望[J]. 中医杂志, 2015, 56(22): 1971-1975. doi: 10.13288/j.11-2166/r.2015.22.023 WEI C, JIA ZH, CHANG LP. Review and prospect of research in the discipline of TCM collateral diseases[J]. J Tradit Chin Med, 2015, 56(22): 1971-1975. doi: 10.13288/j.11-2166/r.2015.22.023
[6]	喻昌. 医门法律[M]. 北京: 人民卫生出版社, 2006: 19. YU C. Precepts for Physicians[M]. Beijing: People's medical publishing house, 2006: 19.
[7]	叶天士. 临证指南医案[M]. 上海: 上海科学技术出版社, 1959. YE TS. Case Records as A Guide to Clinical Practice[M]. Shanghai: Shanghai science and technology press, 1959.
[8]	吴以岭. 中医络病学说与三维立体网络系统[J]. 中医杂志, 2003, 44(6): 407-409. doi: 10.3321/j.issn:1001-1668.2003.06.002 WU YL. Theory of TCM collateral diseases and the three-dimensional network system[J]. J Tradit Chin Med, 2003, 44(6): 407-409. doi: 10.3321/j.issn:1001-1668.2003.06.002
[9]	吴以岭. 络病学概要[J]. 疑难病杂志, 2004, 3(1): 37-39. doi: 10.3969/j.issn.1671-6450.2004.01.017 WU YL. Summary of the theory of collateral diseases[J]. J Diffcult Complicat Cases, 2004, 3(1): 37-39. doi: 10.3969/j.issn.1671-6450.2004.01.017
[10]	吴以岭. 络病病因探析[J]. 疑难病杂志, 2004, 3(4): 215-217. doi: 10.3969/j.issn.1671-6450.2004.04.008 WU YL. Investigation of the etiology of collateral diseases[J]. J Diffcult Complicat Cases, 2004, 3(4): 215-217. doi: 10.3969/j.issn.1671-6450.2004.04.008
[11]	吴以岭. 络病病机探析[J]. 中医杂志, 2005, 46(4): 243-245. doi: 10.3321/j.issn:1001-1668.2005.04.001 WU YL. Exploration of the pathogenesis of collateral diseases[J]. J Tradit Chin Med, 2005, 46(4): 243-245. doi: 10.3321/j.issn:1001-1668.2005.04.001
[12]	吴以岭. 络病的十大临床表现(一)[J]. 疑难病杂志, 2005, 4(2): 88-90. doi: 10.3969/j.issn.1671-6450.2005.02.009 WU YL. Ten clinical manifestations of collateral diseases (Ⅰ)[J]. J Diffcult Complicat Cases, 2005, 4(2): 88-90. doi: 10.3969/j.issn.1671-6450.2005.02.009
[13]	吴以岭. 络病的十大临床表现(二)[J]. 疑难病杂志, 2005, 4(3): 155-156. doi: 10.3969/j.issn.1671-6450.2005.03.010 WU YL. Ten clinical manifestations of collateral diseases (Ⅱ)[J]. J Diffcult Complicat Cases, 2005, 4(3): 155-156. doi: 10.3969/j.issn.1671-6450.2005.03.010
[14]	吴以岭. 络病辨证八要[J]. 疑难病杂志, 2005, 4(1): 22-25. doi: 10.3969/j.issn.1671-6450.2005.01.008 WU YL. The eight essentials of syndrome identification of collateral diseases[J]. J Diffcult Complicat Cases, 2005, 4(1): 22-25. doi: 10.3969/j.issn.1671-6450.2005.01.008
[15]	吴以岭. 络病治疗原则与通络药物[J]. 疑难病杂志, 2005, 4(4): 213-215. doi: 10.3969/j.issn.1671-6450.2005.04.008 WU YL. Treatment principles of collaterals disease and medicine to unblocking collaterals[J]. J Diffcult Complicat Cases, 2005, 4(4): 213-215. doi: 10.3969/j.issn.1671-6450.2005.04.008
[16]	袁国强, 魏聪, 吴以岭. 脉络学说历史发展轨迹探析[J]. 疑难病杂志, 2011, 10(12): 922-926. doi: 10.3969/j.issn.1671-6450.2011.12.019 YUAN GQ, WEI C, WU YL. Exploration of the historical development of the pulse-collateral theory[J]. Chin J Difficult Complicat Cases, 2011, 10(12): 922-926. doi: 10.3969/j.issn.1671-6450.2011.12.019
[17]	灵枢经[M]. 北京: 人民卫生出版社, 1963. The Spiritual Pivot[M]. Beijing: People's medical publishing house, 1963.
[18]	张仲景. 精译伤寒杂病论[M]. 北京: 中医古籍出版社, 2003. ZHANG ZJ. Bound Volume of Treatise on Cold Damage and Miscellaneous Diseases and Essentials from the Golden Cabinet[M]. Beijing: Ancient books publishing house of Chinese medicine, 2003.
[19]	袁国强, 吴以岭, 贾振华, 等. 脉络病变辨证方法浅析[J]. 中国中医基础医学杂志, 2011, 17(9): 944-946. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201109006.htm YUAN GQ, WU YL, JIA ZH, et al. Brief analysis of the method of identification of pulse-collateral diseases[J]. Chin J Basic Med Tradit Chin Med, 2011, 17(9): 944-946. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201109006.htm
[20]	吴以岭, 魏聪, 贾振华, 等. 脉络学说概要及其应用[J]. 中医杂志, 2014, 55(3): 181-184. doi: 10.3969/j.issn.0411-8421.2014.03.016 WU YL, WEI C, JIA ZH, et al. A summary of vessels-networks theory and its application[J]. J Tradit Chin Med, 2014, 55(3): 181-184. doi: 10.3969/j.issn.0411-8421.2014.03.016
[21]	吴以岭. 脉络论[M]. 北京: 中国科学技术出版社, 2010. WU YL. Pulse-Collateral Theory[M]. Beijing: China science and technology press, 2010.
[22]	吴以岭, 魏聪, 赵珊珊. 气与气络学说探讨[J]. 中医杂志, 2017, 58(21): 1801-1807. doi: 10.13288/j.11-2166/r.2017.21.001 WU YL, WEI C, ZHAO SS. Qi and qi-collateral theory[J]. J Tradit Chin Med, 2017, 58(21): 1801-1807. doi: 10.13288/j.11-2166/r.2017.21.001
[23]	吴以岭, 赵珊珊, 魏聪. 试论气络学说研究思路: "形而上"的哲学思维与"形而下"的医学格物致知相结合[J]. 疑难病杂志, 2017, 16(8): 757-760. doi: 10.3969/j.issn.1671-6450.2017.08.001 WU YL, ZHAO SS, WEI C. The discussion on the research thinking of construction of qi-collaterals—the combination of philosophical thinking of "metaphysics" and medical practical activities of "physics"[J]. Chin J Difficult Complicat Cases, 2017, 16(8): 757-760. doi: 10.3969/j.issn.1671-6450.2017.08.001
[24]	吴以岭. 气络学说论: 《气络论》序[J]. 疑难病杂志, 2018, 17(2): 184-186. doi: 10.3969/j.issn.1671-6450.2018.02.020 WU YL. Discussions on qi-collateral theory: Preface to the Qi-collateral theory[J]. Chin J Difficult Complicat Cases, 2018, 17(2): 184-186. doi: 10.3969/j.issn.1671-6450.2018.02.020
[25]	贾振华, 吴以岭. 络病理论指导外感温病研究[J]. 环球中医药, 2010, 3(1): 26-28. doi: 10.3969/j.issn.1674-1749.2010.01.007 JIA ZH, WU YL. The research of exogenous febrile disease guided by the collateral disease theory[J]. Glob Tradit Chin Med, 2010, 3(1): 26-28. doi: 10.3969/j.issn.1674-1749.2010.01.007
[26]	朱舜亚, 李晓萸, 魏云玲, 等. 三种中药处方对SARS相关冠状病毒体外抑制作用的初步研究[J]. 生物技术通讯, 2003, 14(5): 390-392. doi: 10.3969/j.issn.1009-0002.2003.05.012 ZHU SY, LI XY, WEI YL, et al. Inhibitory effects of three prescriptions of traditional Chinese medicine on SARS-associated coronavirus in vitro[J]. Lett Biotechnol, 2003, 14(5): 390-392. doi: 10.3969/j.issn.1009-0002.2003.05.012
[27]	DUAN ZP, JIA ZH, ZHANG J, et al. Natural herbal medicine Lianhua Qingwen capsule anti-influenza A (H1N1) trial: A randomized, double blind, positive controlled clinical trial[J]. Chin Med J, 2011(18): 2925-2933.
[28]	莫红缨, 柯昌文, 郑劲平, 等. 连花清瘟胶囊体外抗甲型流感病毒的实验研究[J]. 中药新药与临床药理, 2007, 18(1): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY200701002.htm MO HY, KE CW, ZHENG JP, et al. Anti-viral effects of Lianhua Qingwen capsule against influenza A virus in vitro[J]. Tradit Chin Drug Res Clin Pharmacol, 2007, 18(1): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY200701002.htm
[29]	DING YW, ZENG LJ, LI RF, et al. The Chinese prescription Lianhua Qingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function[J]. BMC Complement Altern Med, 2017, 17: 130. doi: 10.1186/s12906-017-1585-7
[30]	刘晓燕. 连花清瘟胶囊对病毒抑制作用的初步研究[D]. 昆明: 昆明理工大学, 2015. LIU XY. Preliminary study on the viral inhibitory effect of Lianhua Qingwen capsule[D]. Kunming: Kunming University of Science and Technology, 2015.
[31]	窦颖, 杨叁平. 连花清瘟胶囊: 天然抗生素, 广谱抗病毒[J]. 中国社区医师, 2012, 28(35): 9. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS201235010.htm DOU Y, YANG SP. Lianhua Qingwen capsule: A natural antibiotic, broad-spectrum antiviral[J]. Chin Community Dr, 2012, 28(35): 9. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS201235010.htm
[32]	刘更新, 张艳霞, 杨继清, 等. 连花清瘟胶囊治疗甲型H1N1流感随机对照临床研究[J]. 疑难病杂志, 2010, 9(1): 14-16. https://www.cnki.com.cn/Article/CJFDTOTAL-YNBZ201001009.htm LIU GX, ZHANG YX, YANG JQ, et al. The randomized controlled study of Lianhua Qingwen capsule in treating A/H1N1 influenza[J]. Chin J Difficult Complicat Cases, 2010, 9(1): 14-16. https://www.cnki.com.cn/Article/CJFDTOTAL-YNBZ201001009.htm
[33]	谭杜勋, 石文磊, 刘楠, 等. 连花清瘟胶囊在新冠肺炎中早期抗病毒、抗炎的疗效观察[J]. 中国处方药, 2021, 19(5): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202105045.htm TAN DX, SHI WL, LIU N, et al. Early antiviral and anti-inflammatory efficacy of Lianhua Qingwen capsule in coronavirus pneumonia[J]. J China Prescr Drug, 2021, 19(5): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202105045.htm
[34]	LI RF, HOU YL, HUANG JC, et al. Lianhua Qingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)[J]. Pharmacol Res, 2020, 156: 104761. doi: 10.1016/j.phrs.2020.104761
[35]	HU K, GUAN WJ, BI Y, et al. Efficacy and safety of Lianhua Qingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial[J]. Phytomedicine, 2021, 93: 153775.
[36]	吕睿冰, 王文菊, 李欣. 连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察[J]. 中医杂志, 2020, 61(8): 655-659. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202008004.htm LYU RB, WANG WJ, LI X. Combined with western medicine conventional therapy in the treatment of 63 suspected cases of coronavirus disease 2019[J]. J Tradit Chin Med, 2020, 61(8): 655-659. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202008004.htm
[37]	程德忠, 李毅. 连花清瘟颗粒治疗54例新型冠状病毒肺炎患者临床分析及典型病例报道[J]. 世界中医药, 2020, 15(2): 150-154. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA202002006.htm CHENG DZ, LI Y. Clinical effectiveness and case analysis in 54 NCP patients treated with lanhuaqingwen granules[J]. World Chin Med, 2020, 15(2): 150-154. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA202002006.htm
[38]	GONG XW, YUAN BY, YUAN YD, et al. Efficacy and safety of Lianhua Qingwen Capsules for the prevention of coronavirus disease 2019: A prospective open-label controlled trial[J]. Evid Based Complementary Altern Med, 2021, 2021: 7962630.
[39]	李红蓉, 常丽萍, 魏聪, 等. 连花清瘟治疗新型冠状病毒肺炎的理论研究基础和临床疗效[J]. 世界中医药, 2020, 15(3): 332-336. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA202003006.htm LI HR, CHANG LP, WEI C, et al. Theoretical research basis and clinical efficacy of Lianhua Qingwen in treating novel coronavious pneumonica[J]. World Chin Med, 2020, 15(3): 332-336. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA202003006.htm
[40]	尹玉洁, 常丽萍. 中药连花清瘟胶囊/颗粒在呼吸系统疾病中的药理研究及临床应用进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1174-1180. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL202110010.htm YIN YJ, CHANG LP. Pharmacological research and clinical applications progress of Lianhua Qingwen Capsules/Granules in respiratory diseases[J]. Chin J Clin Pharmacol Ther, 2021, 26(10): 1174-1180. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL202110010.htm
[41]	贾振华, 高怀林, 谷春华, 等. 基于3 469例血管病变患者证候分布规律的脉络病变共性病机探讨[J]. 中医杂志, 2009, 50(10): 920-924. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ200910032.htm JIA ZH, GAO HL, GU CH, et al. Research on common pathogenesis of vessel diseases of 3 469 patients based on TCM syndrome distribution[J]. J Tradit Chin Med, 2009, 50(10): 920-924. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ200910032.htm
[42]	贾振华, 吴以岭, 高怀林, 等. "脉络-血管系统病"辨证诊断标准[J]. 中医杂志, 2007(11): 1027-1032. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ200711035.htm JIA ZH, WU YL, GAO HL, et al. Diagnostic criteria for the syndrome identification of "pulse-collateral-vascular system diseases"[J]. J Tradit Chin Med, 2007(11): 1027-1032. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ200711035.htm
[43]	梁永, 游东, 敖小姬. 通心络治疗42例冠心病心绞痛的临床疗效观察[J]. 现代诊断与治疗, 2015, 26(3): 660-661. LIANG Y, YOU D, AO XJ. Clinical efficacy of Tongxinluo in the treatment of 42 cases of angina pectoris in coronary heart disease[J]. Mod Diagn Treat, 2015, 26(3): 660-661.
[44]	白清. 通心络胶囊与补阳还五汤对糖尿病合并不稳定型心绞痛相关调节因子影响对比[J]. 中成药, 2015, 37(4): 732-735. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201504009.htm BAI Q. Comparison of Buyang Huanwu Decoction and Tongxinluo Capsules on platelet, endothelial function and inflammatory factor of diabetes patients with unstable angina[J]. Chin Tradit Pat Med, 2015, 37(4): 732-735. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201504009.htm
[45]	张孟军. 通心络对脑动脉硬化症患者血液流变学的影响[J]. 临床合理用药杂志, 2015, 8(11): 50-51. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY201511034.htm ZHANG MJ. Effect of Tongxinluo on blood rheology in patients with cerebral arteriosclerosis[J]. Chin J Clin Ration Drug Use, 2015, 8(11): 50-51. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY201511034.htm
[46]	李红蓉, 张肖, 常丽萍, 等. 通心络胶囊抗动脉粥样硬化研究进展[J]. 中成药, 2016, 38(2): 386-391. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201602033.htm LI HR, ZHANG X, CHANG LP, et al. Research progress of Tongxinluo capsule against atherosclerosis[J]. Chin Tradit Pat Med, 2016, 38(2): 386-391. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201602033.htm
[47]	曹鸿雁, 秦玲, 黄可欣. 通心络对家兔动脉粥样硬化模型MMP-3, 9及PPAR_γ表达的影响[J]. 南方医科大学学报, 2009, 29(9): 1887-1889. https://www.cnki.com.cn/Article/CJFDTOTAL-DYJD200909039.htm CAO HY, QIN L, HUANG KX. Effects of Tongxinluo on MMP-3, 9 and PPAR_γ expressions in atherosclerotic rabbits[J]. J South Med Univ, 2009, 29(9): 1887-1889. https://www.cnki.com.cn/Article/CJFDTOTAL-DYJD200909039.htm
[48]	刘美之, 贾振华, 魏聪, 等. 通心络超微粉对兔动脉粥样硬化早期外膜微血管新生的影响[J]. 中医杂志, 2015, 56(3): 240-245. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201503024.htm LIU MZ, JIA ZH, WEI C, et al. Influence of Tongxinluo ultrafine powder on early atherosclerotic epicardial angiogenesis[J]. J Tradit Chin Med, 2015, 56(3): 240-245. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201503024.htm
[49]	张运. 通心络可稳定AS兔动脉易损斑块, 防止破裂[J]. 医学研究杂志, 2008, 37(5): 1-2. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ200805000.htm ZHANG Y. Effects of Tongxinluo in stabilizing vulnerable plaques and preventing rupture in AS rabbit arteries[J]. J Med Res, 2008, 37(5): 1-2. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ200805000.htm
[50]	ZHANG M, LIU Y, XU MJ, et al. Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study[J]. Sci Rep, 2019, 9: 4545.
[51]	关启刚, 曾定尹, 孙喜琢, 等. 通心络对IL-1β介导的小型猪冠状动脉内膜增殖及5-HT诱发的冠状动脉痉挛的抑制作用[J]. 中国中西医结合杂志, 2008, 28(7): 627-631. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ200807018.htm GUAN QG, ZENG DY, SUN XZ, et al. Inhibitory effect and acting mechanism of Tongxinluo on IL-1β-mediated coronary intimal hyperplasia and 5-hydroxytryptamine-induced coronary vasospasm in small swine[J]. Chin J Integr Tradit West Med, 2008, 28(7): 627-631. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ200807018.htm
[52]	位庚, 梁俊清, 姚兵, 等. 通心络干预的心肌微血管内皮细胞条件培养液对大鼠心肌细胞凋亡的影响[J]. 中国循环杂志, 2018, 33(3): 279-284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201803018.htm WEI G, LIANG JQ, YAO B, et al. Effect of Tongxinluo treated conditioned medium of cardiac microvascular endothelial cells on rats' embryo cardiomyocyte apoptosis[J]. Chin Circ J, 2018, 33(3): 279-284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201803018.htm
[53]	贾振华, 杨跃进. 中药通心络防治急性ST段抬高型心肌梗死心肌无再流中国专家共识(2022年)[J]. 疑难病杂志, 2022, 21(7): 675-682. https://www.cnki.com.cn/Article/CJFDTOTAL-YNBZ202207023.htm JIA ZH, YANG YJ. Chinese expert consensus on the prevention and treatment of acute ST-segment elevation myocardial infarction without myocardial reflow with Chinese herbal medicine Tongxinluo (2022)[J]. Chin J Difficult Complicat Cases, 2022, 21(7): 675-682. https://www.cnki.com.cn/Article/CJFDTOTAL-YNBZ202207023.htm
[54]	ZHANG HT, JIA ZH, ZHANG J, et al. No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: A randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial)[J]. Chin Med J (Engl), 2010, 123(20): 2858-2864.
[55]	LIU S, WEI C, KANG N, et al. Chinese medicine Tongxinluo capsule alleviates cerebral microcirculatory disturbances in ischemic stroke by modulating vascular endothelial function and inhibiting leukocyte-endothelial cell interactions in mice: A two-photon laser scanning microscopy study[J]. Microcirculation. 2018, 25(2): 1-14.
[56]	吕昀, 李学玲, 李文战, 等. 通心络对脑梗死大鼠的神经保护作用[J]. 中国实用神经疾病杂志, 2009, 12(15): 37-38. https://www.cnki.com.cn/Article/CJFDTOTAL-HNSJ200915017.htm LV Y, LI XL, LI WZ, et al. Protective effects of Tongxinluo on neurological function in cerebral rats infarction[J]. Chin J Pract Nerv Dis, 2009, 12(15): 37-38. https://www.cnki.com.cn/Article/CJFDTOTAL-HNSJ200915017.htm
[57]	SHEN S, HOU YL, WU YL. Tongxinluo preserves the renal function in diabetic kidney disease via protecting the HK-2 cells from the patterns of programmed cell death[J]. Bangladesh J Pharmacol, 2021, 16(2): 52-64. http://www.xueshufan.com/publication/3189286570
[58]	张军芳, 魏聪, 王宏涛, 等. 参松养心胶囊整合调节心律失常的研究进展[J]. 中国中医基础医学杂志, 2016, 22(1): 144-146. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201601056.htm ZHANG JF, WEI C, WANG HT, et al. Research progress on the integrated regulation of cardiac arrhythmias by Shensong Yangxin capsule[J]. J Basic Chin Med, 2016, 22(1): 144-146. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201601056.htm
[59]	贾振华. 参松养心胶囊整合调节心律失常的特点[J]. 中国社区医师, 2011, 27(2): 10. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS201102014.htm JIA ZH. Characteristics of Shensong Yangxin Capsules in integrating cardiac arrhythmia regulation[J]. Chin Community Dr, 2011, 27(2): 10. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS201102014.htm
[60]	ZOU JG, ZHANG J, JIA ZH, et al. Evaluation of the traditional Chinese medicine Shensongyangxin capsule on treating premature ventricular contractions: A randomized, double-blind, controlled multicenter trial[J]. Chin Med J (Engl), 2011, 124(1): 76-83.
[61]	汪爱虎, 浦介麟, 齐小勇. 参松养心胶囊治疗阵发性心房颤动的多中心临床研究[J]. 中国社区医师, 2012, 28(13): 9. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS201213011.htm WANG AH, PU JL, QI XY. Multicenter clinical study on the treatment of paroxysmal atrial fibrillation with Shensong Yangxin Capsules[J]. Chin Community Dr, 2012, 28(13): 9. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS201213011.htm
[62]	LIU YF, LI N, JIA ZH, et al. Chinese medicine shensongyangxin is effective for patients with bradycardia: Results of a randomized, double-blind, placebo-controlled multicenter trial[J]. Evid Based Complementary Altern Med, 2014, 2014: 605714.
[63]	WANG X, HU D, DANG S, et al. Effects of traditional Chinese medicine shensong Yangxin Capsules on heart rhythm and function in congestive heart failure patients with frequent ventricular premature complexes[J]. Chin Med J, 2017, 130(14): 1639-1647.
[64]	ZHANG FX, ZOU JG, YU H, et al. Acute efficacy of a traditional Chinese medicine for treatment of frequent premature ventricular contractions in patients with concomitant sinus bradycardia: Results from a double-blind, placebo-controlled, multicentre, randomized clinical trial[J]. Evid Based Complementary Altern Med, 2019, 2019: 3917282.
[65]	李明浩. 参松养心胶囊治疗心律失常的研究进展[J]. 内蒙古中医药, 2020, 39(2): 166-167. https://www.cnki.com.cn/Article/CJFDTOTAL-NZYY202002097.htm LI MH. Research progress on the treatment of cardiac arrhythmia with Shensong Yangxin Capsules[J]. Inner Mongolia J Tradit Chin Med, 2020, 39(2): 166-167. https://www.cnki.com.cn/Article/CJFDTOTAL-NZYY202002097.htm
[66]	魏聪, 贾振华, 袁国强, 等. 整合调节: 心律失常药物干预新策略从"抗律"到"调律"的思维转变[J]. 中华心律失常学杂志, 2014, 18(1): 76-78. https://www.cnki.net/KCMS/detail/detail.aspx?dbcode=IPFD&filename=ZHLB201702001042&dbname=IPFDLAST2018 WEI C, JIA ZH, YUAN GQ, et al. Integration and regulation—new strategy of arrhythmia drug intervention from anti-heart rhythm to regulate heart rhythm[J]. Chin J Cardiac Arrhythm, 2014, 18(1): 76-78. https://www.cnki.net/KCMS/detail/detail.aspx?dbcode=IPFD&filename=ZHLB201702001042&dbname=IPFDLAST2018
[67]	张军芳, 魏聪, 王宏涛, 等. 从脉络学说探讨慢性心力衰竭病机[J]. 中医杂志, 2014, 55(13): 1086-1089. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201413004.htm ZHANG JF, WEI C, WANG HT, et al. Exploring the pathogenesis of chronic heart failure from the pulse-collateral theory[J]. J Tradit Chin Med, 2014, 55(13): 1086-1089. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201413004.htm
[68]	朱静华, 吕洋, 梁明, 等. 芪苈强心胶囊治疗慢性心力衰竭研究进展[J]. 临床军医杂志, 2019, 47(10): 1137-1138. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ201910045.htm ZHU JH, LYU Y, LIANG M, et al. Research progress of Qili Qiangxin capsule in the treatment of chronic heart failure[J]. Clin J Med Off, 2019, 47(10): 1137-1138. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ201910045.htm
[69]	赵齐飞, 李红蓉, 尹玉洁, 等. 芪苈强心胶囊治疗慢性心力衰竭作用机制研究进展[J]. 天津中医药, 2019, 36(4): 313-318. https://www.cnki.com.cn/Article/CJFDTOTAL-TJZY201904001.htm ZHAO QF, LI HR, YIN YJ, et al. Research progress on the effect and mechanism of Qili Qiangxin Capsule in treating chronic heart failure[J]. Tianjin J Tradit Chin Med, 2019, 36(4): 313-318. https://www.cnki.com.cn/Article/CJFDTOTAL-TJZY201904001.htm
[70]	赵之农, 王琦, 邹云增. 芪苈强心胶囊治疗心血管系统疾病的研究进展[J]. 国际中医中药杂志, 2019(7): 785-789. ZHAO ZN, WANG Q, ZOU YZ. The review of Qili-Qiangxin capsule's effect on the cardiovascular diseases[J]. Int J Tradit Chin Med, 2019(7): 785-789.
[71]	LI XL, ZHANG J, HUANG J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili Qiangxin Capsules in patients with chronic heart failure[J]. J Am Coll Cardiol, 2013, 62(12): 1065-1072.
[72]	李红蓉, 魏聪, 集川原, 等. 八子补肾胶囊的抗衰老研究进展[J]. 中国实验方剂学杂志, 2022, 28(7): 239-246. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202207029.htm LI HR, WEI C, JI CY, et al. Bazi bushen Capsules on anti-aging: A review[J]. Chin J Exp Tradit Med Formulae, 2022, 28(7): 239-246. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202207029.htm
[73]	HUANG D, WANG XD, ZHU YH, et al. Bazi bushen capsule alleviates post-menopausal atherosclerosis via GPER1-dependent anti-inflammatory and anti-apoptotic effects[J]. Front Pharmacol, 2021, 12: 658998.
[74]	HUANG D, HU HW, CHANG LP, et al. Chinese medicine Bazi Bushen capsule improves lipid metabolism in ovariectomized female ApoE^-/- mice[J]. Ann Palliat Med, 2020, 9(3): 1073-1083.
[75]	LI L, ZHANG H, CHEN BB, et al. BaZiBuShen alleviates cognitive deficits and regulates Sirt6/NRF2/HO-1 and Sirt6/P53-PGC-1α-TERT signaling pathways in aging mice[J]. J Ethnopharmacol, 2022, 282: 114653.
[76]	李蕊, 李琳, 田怿淼, 等. 八子补肾胶囊对衰老小鼠骨质量的保护作用及其对SIRT6/NF-κB/cathepsin K通路的影响[J]. 中国骨质疏松杂志, 2021, 27(3): 313-318, 328. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202103003.htm LI R, LI L, TIAN YM, et al. Bazi Bushen Capsules improves bone quality and regulates SIRT6/NF-κB/cathepsin K pathway in aged mice[J]. Chin J Osteoporos, 2021, 27(3): 313-318, 328. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202103003.htm
[77]	LI L, CHEN BB, AN T. BaZiBuShen alleviates altered testicular morphology and spermatogenesis and modulates Sirt6/P53 and Sirt6/NF-κB pathways in aging mice induced by D-galactose and NaNO 2[J]. J Ethnopharmacol, 2021, 271: 113810.
[78]	王启荣, 方子龙, 郑义, 等. 补充八子补肾胶囊对男子足球运动员赛前准备期和比赛期血液生化指标和运动能力的影响[J]. 中国运动医学杂志, 2012, 31(12): 1054-1058. https://www.cnki.com.cn/Article/CJFDTOTAL-YDYX201212002.htm WANG QR, FANG ZL, ZHENG Y, et al. Chinese tonifying formula Bazi Bushen Capsules benefits the performance of soccer players during preparation and competition period[J]. Chin J Sports Med, 2012, 31(12): 1054-1058. https://www.cnki.com.cn/Article/CJFDTOTAL-YDYX201212002.htm
[79]	李永利, 陈金亮, 李建军, 等. 八子王胶囊治疗阳痿240例临床观察[J]. 河北中医, 1997, 19(6): 6-7. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZY199706004.htm LI YL, CHEN JL, LI JJ, et al. Clinical observation of 240 cases of impotence treated with Baziwang capsule[J]. Hebei J Tradit Chin Med, 1997, 19(6): 6-7. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZY199706004.htm